Lucentis Biosimilar To Be Sold To Emerging Markets By Xbrane Biopharma
This article was originally published in Scrip
Executive Summary
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.